Finance

Lists
BBOT:NASDAQ
BridgeBio Oncology Therapeutics Inc
$5.52
-18.28%
(-1.24) 1D
$5.41
-1.99% (-0.11)
Pre-market
Closed: Sep 10, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BBOT...
Open
$6.78
High
$6.78
Low
$5.48
Mkt. cap
442.23M
Avg. vol.
301.13K
Volume
5.42K
52-wk high
$14.87
52-wk low
$5.48
EPS
-$3.04
Shares outstanding
80.17M
No. of employees
88
Open
$6.78
High
$6.78
Low
$5.48
Mkt. cap
442.23M
Avg. vol.
301.13K
Volume
5.42K
52-wk high
$14.87
52-wk low
$5.48
EPS
-$3.04
Shares outstanding
80.17M
No. of employees
88
News stories
From web sources and news partners
About BridgeBio Oncology Therapeutics Inc
CEO-
Employees88
Founded2016
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitebbotx.com
Analyst ratings
Based on 9 analysts giving stock ratings to BBOT in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for BBOT in the last 3 months.
Highest
Current $5.52
$27.00 (+389.13%)
Average
$21.44 (+288.41%)
Lowest
$15.00 (+171.74%)
Analyst
Recommendation
Action
Price target
Projected
Date
Priyanka Grover
J.P. Morgan
Buy
Reiterated
$23.00
+316.7%
09/11/2026
Andrew Berens
Leerink Partners
Buy
Reiterated
$27.00
+389.1%
09/10/2026
Unknown Analyst
Wedbush
Buy
Maintained
$25.00
+352.9%
09/09/2026
Biren Amin
Piper Sandler
Buy
Maintained
$21.00
+280.4%
09/09/2026
Sean McCutcheon
Raymond James
Buy
Maintained
$22.00
+298.6%
09/09/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
$15.00
+171.7%
09/09/2026
John Newman
Canaccord Genuity
Buy
Maintained
$20.00
+262.3%
09/09/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
$18.00
+226.1%
08/17/2026
Unknown Analyst
J.P. Morgan
Buy
Reiterated
$25.00
+352.9%
08/14/2026
Mazahir Alimohamed
Oppenheimer
Buy
Reiterated
$22.00
+298.6%
08/12/2026
David Nierengarten
Wedbush
Buy
Maintained
$25.00
+352.9%
05/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$22.00
+298.6%
05/13/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$29.00
+425.4%
05/01/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
35.05M
38.07M
39.80M
49.22M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14.13M
5.33M
6.38M
10.96M
Operating expense
49.18M
43.41M
46.18M
60.19M
Total operating expenses
49.18M
43.41M
46.18M
60.19M
Operating income
-49.18M
-43.41M
-46.18M
-60.19M
Other non operating income
980.00K
187.00K
129.00K
182.00K
EBT including unusual items
-44.76M
-38.80M
-42.11M
-56.45M
EBT excluding unusual items
-44.76M
-38.80M
-42.11M
-56.45M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-44.76M
-38.80M
-42.11M
-56.45M
Net profit margin
-
-
-
-
Earnings per share
-1.03
-0.49
-0.53
-0.71
Interest and investment income
3.44M
4.42M
3.94M
3.55M
Interest expense
-
-
-
-
Net interest expenses
3.44M
4.42M
3.94M
3.55M
Depreciation and amortization charges
-
-
-
-
EBITDA
-49.11M
-43.32M
-46.10M
-60.11M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps